Search

Protego Biopharma Heteroaryl Diamide IRE1/XBP1S Activator Patent EP4347568A1

The European Patent Office published patent application EP4347568A1 on 15 April 2026, filed by Protego Biopharma, Inc. and The Scripps Research Institute, covering heteroaryl diamide compounds as IRE1/XBP1S pathway activators. The application lists eight named inventors and spans multiple therapeutic classifications including metabolic, cardiovascular, musculoskeletal, and neurological disease indications. The patent is now publicly available and designates all EPC contracting states across the EU and beyond.